AKTX-101 / Akari Therap - LARVOL DELTA

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "Upcoming Expected Value-Driving Milestones: Next-Generation Precision Bi-Functional ADC Platform - Present anticipated PH1 Payload preclinical data at scientific conference; Complete additional preclinical studies for AKTX-101; Continue to advance pipeline by generating additional validating data on PH1 payload while advancing discovery work on additional novel payloads PH5 and PH6....Seek licensing/strategic partner for AKTX-101 (TROP2 PH1 ADC)."

Licensing / partnership • Preclinical • Oncology • Solid Tumor

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire) - "Akari Therapeutics...and Peak Bio...announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX....The merged pipeline features a robust ADC toolkit with novel payload and linker technologies. By combining chemotherapy with immunotherapy strategies, the merged company aims to develop cutting-edge solutions for cancer patients. In addition, the program includes a novel pre-clinical ADC candidate targeting TROP-2."

M&A • Oncology

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting (GlobeNewswire) - "These data highlight the rationale for the clinical development of Trop2 PH1 ADC as an investigational therapeutic for the treatment of solid cancers. Trop2 ADCs, conjugated with PH1 toxin at a drug-to-antibody (DAR) ratio of 4, demonstrated single digit nanomolar potency in eight different solid tumor indications....The unique design of the Trop2 PH1 ADC resulted in minimal off-target effects and demonstrated a differentiated safety profile versus first-in-class ADCs Furthermore, Trop2 PH1 ADCs exhibited more potent TGI at a lower DAR and dose, than FIC, in gastric cancer model."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Rationale for the development of a differentiated Trop2 ADC (AACR 2023) - "The Trop2 ADC Trodelvy® (also known as Sacituzumab govitecan/ IMMU-132) is approved for therapy of TNBC and urothelial cancer, and Datopotamab DXd (DS-1062) is currently being tested in NSCLC.Peak Bio’s Thailanstatin suite of immunomodulatory linker-toxins (L-Ts) is a set of 7 related molecules with distinct ADC features that have been extensively characterized in vitro and in vivo as Her2 ADCs and is being used as a platform to generate a pipeline of potentially differentiated ADCs (AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1832). M2.8 is a fully humanized Peak Bio antibody (Ab) that targets human Trop2 (hTrop2) with high binding affinity [Kd (M)= 8.97-09]. The target validation studies suggest that Trop2 PH1 ADCs were sufficiently differentiated in areas of preclinical efficacy and well tolerated in a toxicologically relevant host."

Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • HER-2 • TACSTD2